Syntex's
scope of activity extends to many facets of the industry,
with a primary focus on the manufacturing and marketing of
products in the following categories:
Human
pharmaceuticals
-
Syntex
produces generic drugs in all major therapeutics and
steriles in a variety of dosage forms, from tablets and
capsules to ointments, creams and liquids.
-
In
addition, Syntex manufactures innovative drugs in the
markets where it has a relative advantage in efficacy.
Generic pharmaceuticals - A
comprehensive portfolio
Syntex
believes that its product diversity will continue to be of
strategic significance, paralleling the needs of an emerging
and dynamically evolving generic industry deeply affected by
trends of consolidation among managed care providers, large
pharmacy chains, wholesalers and other large-scale buyers.
Syntex Pharmaceuticals
Pakistan, , is the
jewel in the crown of Syntex's international efforts in the
generic pharmaceuticals arena and one of the most successful
manufacturers and distributors of generic drugs in the
Pakistan.
In 2001, Syntex expanded product lines in generics,
including a significant respiratory business, and a rich
pipeline of generic and proprietary products in the areas of
respiratory, CNS and oncology. The company will now offer
the widest range of cost-effective pharmaceuticals, both
generic and branded, to consumers, customers, and healthcare
providers.
R&D -
Innovation at the core
Syntex's innovative products are developed for specialized
markets with the current focus on neurological disorders and
auto-immune diseases. Maintaining ongoing collaborative
efforts with Israel's major universities, hospitals and
research institutes is an important core element of Syntex's
approach to innovative Research and Development. Currently,
Syntex has novel treatments for MS, Parkinson's Disease
(PD), Alzheimer's disease (AD), Amyotrophic Lateral
Sclerosis (ALS) and other CNS indications as well as
Systemic Lupus Erythematosus in clinical research phases.
